6np0
From Proteopedia
(Difference between revisions)
| Line 3: | Line 3: | ||
<StructureSection load='6np0' size='340' side='right'caption='[[6np0]], [[Resolution|resolution]] 2.92Å' scene=''> | <StructureSection load='6np0' size='340' side='right'caption='[[6np0]], [[Resolution|resolution]] 2.92Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
| - | <table><tr><td colspan='2'>[[6np0]] is a 5 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6NP0 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6NP0 FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[6np0]] is a 5 chain structure with sequence from [http://en.wikipedia.org/wiki/Lk3_transgenic_mice Lk3 transgenic mice]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6NP0 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6NP0 FirstGlance]. <br> |
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=CWB:1-METHYL-N-[(1R,5S)-9-METHYL-9-AZABICYCLO[3.3.1]NONAN-3-YL]INDAZOLE-3-CARBOXAMIDE'>CWB</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=CWB:1-METHYL-N-[(1R,5S)-9-METHYL-9-AZABICYCLO[3.3.1]NONAN-3-YL]INDAZOLE-3-CARBOXAMIDE'>CWB</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr> | ||
| + | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">Htr3a ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=10090 LK3 transgenic mice])</td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6np0 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6np0 OCA], [http://pdbe.org/6np0 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6np0 RCSB], [http://www.ebi.ac.uk/pdbsum/6np0 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6np0 ProSAT]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6np0 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6np0 OCA], [http://pdbe.org/6np0 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6np0 RCSB], [http://www.ebi.ac.uk/pdbsum/6np0 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6np0 ProSAT]</span></td></tr> | ||
</table> | </table> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | Serotonin receptor (5-HT3AR) is the most common therapeutic target to manage the nausea and vomiting during cancer therapies and in the treatment of irritable bowel syndrome. Setrons, a class of competitive antagonists, cause functional inhibition of 5-HT3AR in the gastrointestinal tract and brainstem, acting as effective anti-emetic agents. Despite their prevalent use, the molecular mechanisms underlying setron binding and inhibition of 5-HT3AR are not fully understood. Here, we present the structure of granisetron-bound full-length 5-HT3AR solved by single-particle cryo-electron microscopy to 2.92 A resolution. The reconstruction reveals the orientation of granisetron in the orthosteric site with unambiguous density for interacting sidechains. Molecular dynamics simulations and electrophysiology confirm the granisetron binding orientation and the residues central for ligand recognition. Comparison of granisetron-bound 5-HT3AR with the apo and serotonin-bound structures, reveals key insights into the mechanism underlying 5-HT3AR inhibition. | ||
| + | |||
| + | Molecular mechanism of setron-mediated inhibition of full-length 5-HT3A receptor.,Basak S, Gicheru Y, Kapoor A, Mayer ML, Filizola M, Chakrapani S Nat Commun. 2019 Jul 19;10(1):3225. doi: 10.1038/s41467-019-11142-8. PMID:31324772<ref>PMID:31324772</ref> | ||
| + | |||
| + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
| + | </div> | ||
| + | <div class="pdbe-citations 6np0" style="background-color:#fffaf0;"></div> | ||
| + | == References == | ||
| + | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
| + | [[Category: Lk3 transgenic mice]] | ||
[[Category: Basak, S]] | [[Category: Basak, S]] | ||
[[Category: Chakrapani, S]] | [[Category: Chakrapani, S]] | ||
[[Category: Membrane protein]] | [[Category: Membrane protein]] | ||
Revision as of 07:00, 31 July 2019
Cryo-EM structure of 5HT3A receptor in presence of granisetron
| |||||||||||
